Tesamorelin reduced fat around organs among adults living with HIV

The main finding is less unusual belly fat with HIV

Scientists developed tesamorelin to increase growth hormone release within the body. A gland beneath the brain makes this hormone, which helps growth and the use of fat. A blood protein involved in growth rises as well. The approved treatment reduces unusual belly fat buildup in adults living with HIV.

A review combined five trials that assigned treatments by chance ^[12]. The adults lost fat around their organs, across the middle body and in the liver, while muscle and other fat-free tissue increased during the treatment tested. A smaller trial also measured less fat in the belly and liver ^[14].

A longer study found that belly fat stayed lower during treatment. People began regaining that fat after stopping tesamorelin ^[16]. You can't turn those findings into a promise of ordinary weight loss or slower aging. People with other health needs require trials that test those needs in people like them.

The approval does not cover ordinary or cosmetic weight loss

Tesamorelin has a 44-amino-acid makeup, joining the small parts also used in proteins. To resist breakdown inside the body, scientists changed one end. The drug helps the body make growth hormone and release more of the hormone. The drug doesn't supply growth hormone directly as a replacement medicine.

The United States approved tesamorelin in 2010 for unusual belly fat buildup with HIV ^[13]. This condition is lipodystrophy: fat collects or disappears in unusual places. Ordinary obesity and cosmetic fat loss remain outside the approved use. Nor does approval include longer life, sharper thinking or fatty liver treatment without HIV.

A measured change in fat doesn't establish those broader benefits in your situation. These trials involved adults with a certain illness and fat problem. Hormone activity alone can't prove help or safety in another group. The strongest treatment evidence concerns adults with HIV and this unusual fat buildup.

A short test found higher hormone readings in healthy men

Tesamorelin prompts the small gland just under the brain to release bursts of growth hormone. Afterward, the liver makes insulin-like growth factor 1, a protein involved in growth. These changes change the body’s use of fat. Treatment trials mainly found less fat surrounding organs, rather than proving every hoped-for benefit.

A test over two weeks followed 13 healthy men. Growth hormone increased overnight, though that reading doesn't show improved health ^[15]. The growth-related blood protein increased by 181 micrograms per liter of blood, a blood-test measure of the rise. Sugar before eating and insulin's help in using sugar didn't clearly change.

Those blood tests confirm that tesamorelin changed hormone activity in these men. The short test leaves the effects of years of use unknown. Higher hormone readings aren't proof that someone feels better or lives longer. Raising your own hormone release isn't the same as getting growth hormone directly, but the increased growth-related protein still matters to safety.

Belly fat returned after tesamorelin treatment ended

2026: trials brought together. A review combined five trials in adults with HIV who also had unusual fat buildup. Scans showed greater loss of fat surrounding organs with tesamorelin than with comparison treatment. The 95% confidence range allowed for uncertainty and still pointed to fat loss. Fat across the middle body and in the liver also fell, while tissue without fat increased ^[12]; no serious harm was blamed on treatment in these trials ^[12].

Belly and liver fat in a smaller trial. A six-month study followed 50 adults getting HIV treatment. The drug group lost more fat inside the belly: the difference on a scan was −42 square centimeters ^[14]. That measures the area of fat visible on a scan through the belly. The liver scans also showed less fat; neither measure tells you inches lost from a waist.

Hormone changes over a short time. A two-week test found higher overnight growth hormone and a growth-related blood protein ^[15]. Blood sugar before meals didn't clearly change. Nor did the measured response to insulin clearly change. That short test can't settle safety questions about many years of treatment.

Fat during and after longer treatment. A 52-week study gave tesamorelin to 273 people and placebo, an inactive treatment used for comparison, to 137 people. By week 52, fat surrounding organs had fallen 18% from the starting amount ^[16]. Fat began returning when treatment stopped. Sugar changes weren't large enough to cause medical concern in that study.

These studies point to reduced fat surrounding organs among the adults tested. The findings don't establish ordinary weight loss for you. Continued treatment mattered to keeping belly fat lower. The results can't promise permanent fat loss once the medicine ends.

Liver findings were reassuring but long-term safety remains uncertain

These tesamorelin sources supply treatment trials rather than users' personal accounts. The trial review reported no serious side effects in the included studies ^[12]. LiverTox, a medical reference about liver harm from medicines, found no obvious liver injury blamed on the drug ^[13]. That reference judged such injury unlikely in the evidence reviewed.

The liver findings don't settle every possible risk for you. Growth hormone and the growth-related blood protein both increase. The official drug instructions rule out use with active cancer. Questions about cancer after long use remain, and blood sugar can change.

Brief hormone tests leave years of treatment unanswered, and those gaps matter when claims reach beyond the HIV treatment into uses that researchers haven't tested in people. The 52-week study also found fat returning once treatment ended ^[16]. No clear liver injury ^[13] doesn't establish overall safety or permanent fat loss.

Fat around organs differs from total body weight

The approval concerns adults with HIV and unusual fat collecting within the belly ^[13]. That health problem differs from wanting lower weight on the scales. Describing both as “belly fat loss” can hide that difference. Your diagnosis needs to match the condition actually tested and approved.

Semaglutide and tirzepatide copy food-related hormones affecting hunger and sugar. Tesamorelin prompts more release of growth hormone from the small gland just under the brain. Bremelanotide affects desire through the brain. These different actions lead to different treatment questions and possible harms.

Tesamorelin trials repeatedly measured reduced fat surrounding organs among adults living with HIV ^[12][14][16]. Those results support the finding in the adults who took part. The scans didn't test general waist reduction in everyone. You can't extend the benefit beyond the health problem tested.